Inactive Instrument

Elanix Biotechnologies AG

ELN

DE000A0WMJQ4

Biotechnology & Medical Research

Elanix Biotechnologies AG announced that it has received €1.22 million in funding

August 10, 2016

On August 11, 2016, Elanix Biotechnologies AG (DB:PFTA) closed the transaction. The transaction included participation from three qualifies investors.

Latest news about Elanix Biotechnologies AG

Elanix Biotechnologies AG Announces Executive Changes	20-02-27	CI
Elanix Biotechnologies Ag Reports Earnings Results for the Half Year Ended June 30, 2019	19-09-19	CI
Anja Silling acquired 12.85% stake in Elanix Biotechnologies AG (DB:ELN) from Lee-Ann Laurent-Applegate for €1 million.	19-05-12	CI
Elanix Biotechnologies Ag Announces Nomination of the Chairman of the Supervisory Board, the Vice Chairman and Members of the Board	19-04-18	CI
Elanix Biotechnologies AG Announces Resignation of Jürgen Kullmann from the Supervisory Board	19-02-14	CI
Elanix Biotechnologies AG Announces Change in Supervisory Board	19-02-07	CI
Elanix Plans To Sell Shares Of Company	18-11-23	CI
Elanix Biotechnologies AG (DB:ELN) cancelled the acquisition of Inno 4 Cell AG.	18-08-21	CI
Elanix Biotechnologies AG announced that it has received €0.870298 million in funding	18-06-10	CI
Elanix Biotechnologies AG Appoints Egon Minar to the Joint Role of Chief Operating Officer and Chief Financial Officer	18-05-29	CI
Elanix Biotechnologies AG announced that it expects to receive €0.870298 million in funding	18-05-27	CI
Elanix Biotechnologies AG signs an Agreement with MedBioSante	18-05-23	CI
Elanix Biotechnologies AG announced that it expects to receive €2.5 million in funding from Yorkville Advisors Global LP	18-04-29	CI
Elanix Biotechnologies AG announced that it expects to receive €11 million in funding	18-02-13	CI
Elanix Biotechnologies AG announced that it has received €1.125071 million in funding	18-02-13	CI
Elanix Biotechnologies AG announced a financing transaction	17-12-11	CI
Elanix Biotechnologies Enters into Co-Development Agreement with Dermacon	17-12-03	CI
Elanix Biotechnologies AG Reports Audited Consolidated Earnings Results for the Six Months Ended June 30, 2017; Provides Earnings Guidance for the Financial Year 2017	17-09-29	CI
Elanix Biotechnologies AG (DB:ELN) agreed to acquire Inno 4 Cell AG.	17-08-21	CI
Transwell Biotech Co., Ltd. Starts First Clinical Study with Progenitor Cell Treatment for Skin Graft Wounds	17-07-20	CI
Elanix Biotechnologies AG Starts EU Commercialization of GYNrepair Cream for Women’s Intimate Relief	17-05-31	CI
Elanix Biotechnologies AG Signs an Agreement with Apraxon GmbH	17-04-28	CI
Elanix Biotechnologies AG Signs Agreement with Apraxon to Establish European Logistics Center	17-04-21	CI
Elanix Biotechnologies AG Announces Non-Binding Letter of Intent with Oxford Mestar Ltd. in Regard to Setting Up JV to Market Gynrepair in China	16-11-22	CI
Elanix Biotechnologies AG announced that it has received €1.22 million in funding	16-08-10	CI

Chart Elanix Biotechnologies AG

Duration

Period

More charts

Elanix Biotechnologies AG is a Germany-based provider of solutions for tissue regeneration. The Company develops and commercializes products for acute wound care, dermatological and gynecological applications, and also provides cell technology services. It develops bioresorbable & bioactive skin dressing derived from progenitor skin fibroblasts. The Company's product portfolio comprises Gyn-RepAir cream, which contains a Cell Free Protein Complex (CFPC), and which includes various proteins such as collagen and fibronectin, as well as RepAir-A N cream. The Company also produces validated progenitor skin cells used in drug discovery, toxicity testing and cosmetic applications. It is a spin-out from the University Hospital of Lausanne (CHUV) in Switzerland.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research